Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Cancidas, Caspofungin Acetate. Every FDA application for this active ingredient: 2 branded and 7 generic.
As of Nov 15, 2026, FDA lists 9 applications for Caspofungin Acetate (sold as Cancidas, Caspofungin Acetate), first approved Jan 26, 2001, with 6 new uses approved and 0 published complete response letters.
First approved: Jan 26, 2001
Applications: 9
New uses approved: 6
Complete response letters: 0
Medicare spending, 2025: $1.6M
First approved in the EU: Oct 23, 2001
First approved in Japan: Jan 18, 2012
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Caspofungin Acetate
Part D
$1.6M
+13%
1,041
Cancidas
Part B
$3K
-83%
13
Cancidas
Part D
$0K
-100%
0
Approvals in the EU (EMA)
First approved in the EU 9 months after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
First approved in Japan 132 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
CancidasDrugs with a new additional pediatric dosage indicated for the treatment of febrile neutropenia with suspected fungal infection, esophageal candidiasis,… · MSD K.K. · Dec 18, 2014
Cancidas, new ingredientDrugs with a new active ingredient indicated for the treatment of febrile neutropenia suspected of a fungal infection and fungal infections due to Candida… · MSD K.K. · Jan 18, 2012
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Fresenius Kabi USA
Cipla